29
Participants
Start Date
June 30, 2016
Primary Completion Date
June 29, 2017
Study Completion Date
June 29, 2017
Sulfadoxine-pyrimethamine (low dose)
\- subcurative regimen (500mg/25mg)
Piperaquine (low dose)
\- subcurative regimen (480 mg)
Sulfadoxine-pyrimethamine (high dose)
\- curative regimen (1000mg/50mg)
Piperaquine (high dose)
\- curative regimen (960 mg)
malaria challenge infection, P. falciparum 3D7
malaria challenge infection by P. falciparum 3D7-infected mosquito bites
Atovaquone-proguanil
\- curative regimen: 1000/400 mg, for 3 days
Radboud university medical center, Nijmegen
The PATH Malaria Vaccine Initiative (MVI)
OTHER
QIMR Berghofer Medical Research Institute
OTHER
Radboud University Medical Center
OTHER